ABOUT CENCORA
Cencora combines core pharmaceutical distribution with innovative business solutions to help our partners across the healthcare spectrum get medications to the patients who need them. Biopharmaceutical companies benefit from the global scale and resources of a company ranked #10 on the Fortune 500, combined with local expertise provided by more than 51,000 team members worldwide. Learn more at www.cencora.com.
We help build foundations for successful product submissions, launches, and commercialization across the globe. Our strategic, integrated solutions – encompassing regulatory, safety, market access and more – help accelerate time-to-market while optimizing patient access and revenue from marketed products.
VIDEOS AND WEBINARS
-
![Cencora - CGT Payer Trends]( "Cell And Gene Therapies – U.S. Payer Trends")
Cell And Gene Therapies – U.S. Payer TrendsGain insights from U.S. payer interviews covering coverage processes, evidence requirements, and engagement strategies to accelerate market access from late-stage development through commercialization.
-
![Cencora - AI HEOR Market Access]( "The Transformative Potential Of AI In HEOR And Market Access")
The Transformative Potential Of AI In HEOR And Market AccessHEOR teams are under pressure to move faster without sacrificing rigor. Discover how AI accelerates evidence synthesis, fills data gaps, and supports living models that meet HTA transparency standards.
-
![Cencora - Evolving Policy Landscape]( "The Evolving Policy Landscape: U.S. And EU Pricing And Access")
The Evolving Policy Landscape: U.S. And EU Pricing And AccessU.S. and EU policy shifts are reshaping pricing, access, and launch strategy. Hear expert analysis on IRA, MFN, 340B, EU HTA Regulation, and the Biotech Act to stay ahead of 2025-2026 changes.
-
![Foundations And Implications For International Reference Pricing]( "Foundations And Implications For International Reference Pricing")
Foundations And Implications For International Reference PricingReforms like the U.S. Most Favored Nation model are intensifying pressure on global launch strategies. Understand the tactics that protect value while expanding access.
-
![The Growing Role Of Real-World Evidence]( "The Growing Role Of Real-World Evidence")
The Growing Role Of Real-World EvidenceRegulators and HTA bodies are raising the bar on real-world evidence. Understand how JCAs, oncology registries, and EHR data are redefining what credible RWE looks like, and how to meet agency expectations.
-
![GettyImages-1204037710 meeting]( "Understanding PRCI And Its Requirements")
Understanding PRCI And Its RequirementsNavigating Health Canada's clinical information disclosure process takes real precision and preparation. Ensure your submission stays compliant, on schedule, and ready for review.
CONTACT INFORMATION
Cencora
1 W 1st Ave.
Conshohocken, PA 19428
UNITED STATES
ARTICLES
-
![GettyImages-1132960495 EU European Union flag]( "Understanding The EU Regulatory Landscape For Cell And Gene Therapies")
EU approval for cell and gene therapies isn't just a different process, it's a different playbook. Here's what US manufacturers need to know before they engage.
-
![GettyImages-1367214441 business, meeting]( "Digitized Solutions To Increase Visibility And Streamline Communication Between A PSP And Manufacturer")
When email-based escalation management creates compliance and visibility gaps, a centralized digital solution helps manufacturer and PSP teams act faster and with greater accountability.
-
![Business Meeting-GettyImages-1831418247]( "Cell And Gene Therapy Commercialization Handbook")
Bringing advanced therapeutics to market requires overcoming hurdles in regulation, logistics, and reimbursement. Learn how to coordinate supply chains and implement adaptive strategies for long-term commercial success.
-
![Global networking healthcare-GettyImages-1477437266]( "Evolving And Expanding Global Consulting With Local Expertise")
Experts discuss global market expansion, emphasizing regulatory complexities, product lifecycle investments, and integrating local expertise to ensure successful product launches and long-term market sustainability.
-
![GettyImages-521848481 clinical trial, patient, diversity]( "Partnering With Health Systems: Essential Tips For CGT Commercialization")
Successful cell and gene therapy commercialization requires early, detailed manufacturer collaboration with health systems to ensure scalable operations and seamless patient access beyond the clinical trial.
WHITE PAPERS
-
![Business meeting-GettyImages-2209242819]( "How To Effectively Manage Local Affiliate Pharmacovigilance Outsourcing")
Managing PV across dozens of markets strains even experienced safety teams. Learn about a framework that helps you maintain compliance, reduce risk, and scale confidently into new markets.
-
![iStock-1200038380-stock-finance-chart-CFO]( "International Reference Pricing (IRP): Foundations, Shifts, And What To Do Next")
As global pricing reforms evolve and policies gain traction, stakeholders must critically reassess the role of International Reference Pricing in balancing affordability, access, and incentives for innovation.
-
![GettyImages-1137143869 world map]( "Unlock The Potential Of Pharmacovigilance Outsourcing")
Outsourcing pharmacovigilance can reduce overhead, strengthen compliance, and free teams to focus on innovation. Examine what a well-structured global PV model actually looks like in practice.
PODCASTS
-
![Digital-marketing-GettyImages-1051659276]( "Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty Pharmacy")
Navigating The Digital Era And Beyond For Engaging Key Decision Makers In Specialty PharmacyTune in as experts discuss how biopharma companies can effectively engage healthcare decision-makers in the evolving digital landscape.
-
![Cencora PharmaLex - PlX talks 30]( "An Overview Of Contamination Control Strategy (CCS)")
An Overview Of Contamination Control Strategy (CCS)Join experts Londa Ritchey and Patrick Nieuwenhuizen as they explore the key role of a contamination control strategy in Annex 1 for ensuring patient safety and continuous manufacturing improvement.
-
![Cencora - PharmaLex Talks 28]( "Early Access Programs: What They Are And How To Plan For Them")
Early Access Programs: What They Are And How To Plan For ThemExplore how early access programs are tailored to individual sufferers of rare, ultra-rare, or life-threatening conditions, as well as cohort programs, which target groups of patients afflicted with the same disease.
-
![Cencora - PharmaLex Talks 27]( "Assessing Gaps And Achieving Compliance With Annex 1")
Assessing Gaps And Achieving Compliance With Annex 1In this podcast episode on Annex 1 compliance and gap assessment, Patrick Nieuwenhuizen shares his insights and expertise gleaned from extensive experience in pharmaceutical regulation and compliance.
-
![Cencora - PharmaLex Talks 26]( "Navigating The Process Of Technology Transfer")
Navigating The Process Of Technology TransferOlena Chervonenko, Associate Director Quality Management and Compliance at PharmaLex, provides deeper insights into technology transfer and essential factors for achieving success.
E-BOOKS AND OTHER INSIGHTS
-
![GettyImages-2152658176 oncology, doctor, patient]( "5 Operational Gaps To Avoid CGT Patient Risks")
5 Operational Gaps To Avoid CGT Patient RisksExamine five critical supply chain gaps in cell and gene therapy logistics that put patients at risk, from invisible operational burdens to reactive monitoring and fragmented coordination strategies.
-
![clinical-trials-regulation-GettyImages-2211671788]( "9 Logistics And Distribution Recommendations For CGTs")
9 Logistics And Distribution Recommendations For CGTsCell and gene therapy commercialization requires tailored logistics strategies. Explore nine recommendations covering site readiness, reimbursement gaps, packaging, testing, and coordination.
-
![GettyImages-1132960495 EU European Union flag]( "Understanding The EU Regulatory Landscape For Cell And Gene Therapies")
Understanding The EU Regulatory Landscape For Cell And Gene TherapiesEU approval for cell and gene therapies isn't just a different process, it's a different playbook. Here's what US manufacturers need to know before they engage.
